BARDA Announces Modification to Development Approach for Recombinant Protective Antigen Anthrax Vaccines

PharmAthene's lead product development programs include (1) SparVax(TM) - a second generation recombinant protective antigen (rPA) anthrax vaccine, (2) ValortimA - a fully human monoclonal antibody for the prevention and treatment of anthrax infection, (3) ProtexiaA - a novel bioscavenger for t...

Full description

Saved in:
Bibliographic Details
Published inPR Newswire
Format Newsletter
LanguageEnglish
Published New York PR Newswire Association LLC 07.12.2009
Subjects
Anthrax
Antigens
Biological & chemical weapons
Biomedical research
Funding
Human subjects
Monoclonal antibodies
Press releases
Product development
Request for proposal
Securities markets
Vaccines
Webcasting
ANNAPOLIS, Md
Online AccessGet full text

Cover

More Information
Summary:PharmAthene's lead product development programs include (1) SparVax(TM) - a second generation recombinant protective antigen (rPA) anthrax vaccine, (2) ValortimA - a fully human monoclonal antibody for the prevention and treatment of anthrax infection, (3) ProtexiaA - a novel bioscavenger for the prevention and treatment of morbidity and mortality associated with exposure to chemical nerve agents, (4) RypVax(TM) - a recombinant dual antigen vaccine for plague, and (5) a third generation rPA anthrax vaccine.